16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
The Catholic University of Korea
From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Mutabilis
FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
National Institute of Pharmaceutical Education and Research (NIPER)
Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).
Affinium Pharmaceuticals
Aniline derivative, pharmaceutical composition containing same, and use thereof
Kissei Pharmaceutical
Analysis of the Resistance Mechanism of a Benzoxaborole Inhibitor Reveals Insight into the Leucyl-tRNA Synthetase Editing Mechanism.
Ujf-Embl-Cnrs
Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells.
F. Hoffmann-La Roche
Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors.
TBA
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Glaxosmithkline
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Dupont Pharmaceuticals